✦ LIBER ✦

Participants' Experiences of Being Debriefed to Placebo Allocation in a Clinical Trial

✍ Scribed by Bishop, F. L.; Jacobson, E. E.; Shaw, J.; Kaptchuk, T. J.

Book ID: 115524395
Publisher: SAGE Publications
Year: 2012
Tongue: English
Weight: 306 KB
Volume: 22
Category: Article
ISSN: 1049-7323
DOI: 10.1177/1049732312448544

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Debriefing to placebo allocation: A phen

Debriefing to placebo allocation: A phenomenological study of participants’ experiences in a randomized clinical trial

✍ F. Bishop; E. Jacobsen; J. Shaw; T. Kaptchuk 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 61 KB

Reactions to treatment debriefing among

Reactions to treatment debriefing among the participants of a placebo controlled trial

✍ Zelda Di Blasi; Fay Crawford; Colin Bradley; Jos Kleijnen 📂 Article 📅 2005 🏛 BioMed Central 🌐 English ⚖ 270 KB

110 Motivations of palliative lung cance

110 Motivations of palliative lung cancer patients to participate in a non-placebo clinical trial (QualFRAG)

✍ Edwards, M.; Sivell, S.; Harrop, E.; Nelson, A.; Hood, K.; Griffiths, G.; Byrne, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 44 KB

A qualitative assessment of the experien

A qualitative assessment of the experience of participating in a cancer-related clinical trial

✍ Addie C. Wootten; Jo M. Abbott; Heather M. Siddons; Mark A. Rosenthal; Anthony J 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 123 KB

P05.35. What are participants in clinica

P05.35. What are participants in clinical trials told about placebos? A content analysis of participant information leaflets

✍ Bishop, F; Adams, A; Kaptchuk, T; Lewith, G 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 139 KB

A program for balancing the allocation o

A program for balancing the allocation of subjects to treatment in a clinical trial

✍ Mikel Aickin 📂 Article 📅 1982 🏛 Elsevier Science 🌐 English ⚖ 357 KB

Minimum likelihood allocation (MLA) is a new method for sequentially assigning subjects to treatment groups in a clinical trial. Its aim is to balance the trial, that is, to prevent various treatment groups from containing subjects who have much better or much worse prognoses than the average. The o